Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,027 public trials 2,025 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, Not Recruiting

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

NCT03989414

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Local Institution - 119 Denver, Colorado, United States
  • Local Institution - 104 Tampa, Florida, United States
  • Local Institution - 108 Atlanta, Georgia, United States
  • Local Institution - 112 Chicago, Illinois, United States
View all 49 locations
View Trial Details
Active, Not Recruiting

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT03155191

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Akita University Hospital Akita, Japan
  • University Of Fukui Hospital Yoshida, Fukui, Japan
  • Kyushu University Hospital Higashiku, Fukuoka, Japan
  • Hokkaido University Hospital Sapporo, Hokkaido, Japan
View Trial Details
Active, Not Recruiting

MInimal Residual Disease Adapted Strategy

NCT04934475

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Institut Jules Bordet Brussels, Belgium
  • Cliniques Universitaires Saint-Luc Brussels, Belgium
  • Grand Hôpital de Charleroi - Site de Notre-Dame Charleroi, Belgium
  • Hôpital Jolimont Haine-Saint-Paul, Belgium
View all 73 locations
View Trial Details
Active, Not Recruiting

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

NCT03712202

Conditions
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Lymphocyte-Depleted Classic HL, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, +20 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • City of Hope Medical Center Duarte, California, United States
  • University of California San Diego San Diego, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
View all 17 locations
View Trial Details
Active, Not Recruiting

Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

NCT04475731

Conditions
Acute Lymphoblastic Leukemia, in Relapse, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations
  • Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica Ancona, Italy
  • Area Vasta N. 5 Ascoli Piceno - S. Benedetto Del Tronto, Presidio Ospedaliero Av5 Osp. Gen. Prov.Le "C.G.Mazzoni" - Uoc Ematologia Ascoli Piceno, Italy
  • Ao Di Rilievo Nazionale E Di Alta Specialità "San Giuseppe Moscati" - Avellino - Uoc Ematologia Con Unità Di Trapianto Avellino, Italy
  • Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto Bari, Italy
View all 22 locations
View Trial Details
Active, Not Recruiting

Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL

NCT04624958

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Guangdong General Hospital Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Guangdong Pharmaceutical University Guangzhou, Guangdong, China
View Trial Details

Related conditions